
Yahoo · 14 de sept de 2026
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear t…
VERTEX PHARMACEUTICALS INC
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
No hay suficientes datos históricos para mostrar el gráfico de VRTX.
Precio
$ 8.105
Var. %
-0,79%
Volumen operado
20.169
Precio VRTX
US$ 515,68
Teórico (precio / ratio)
VRTX ÷ 101
US$ 5,11
Sí, existe el CEDEAR de VRTX (VERTEX PHARMACEUTICALS INC) en la Bolsa de Comercio de Buenos Aires (BYMA). Su ticker local es VRTX.
El ticker del CEDEAR de VERTEX PHARMACEUTICALS INC en Argentina es VRTX. La acción subyacente cotiza en NYSE con el símbolo VRTX.
El CEDEAR VRTX tiene un ratio de 101:1. Eso significa que 101 CEDEARs equivalen a 1 acción de VRTX.
El CEDEAR VRTX cotiza hoy a $ 8.105 en pesos argentinos, con una variación diaria de -0,79%.
La acción subyacente VRTX (VERTEX PHARMACEUTICALS INC) cotiza a US$ 515,68 en su mercado de origen (NYSE).

Yahoo · 14 de sept de 2026
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear t…

Yahoo · 14 de sept de 2026
Vertex Pharmaceuticals (NASDAQ:VRTX) is continuing to broaden its business beyond cystic fibrosis, with its renal medicine portfolio, rare endocrine assets and…

Yahoo · 14 de sept de 2026
Lonquist to lead survey planning and data acquisition, building on recent technical work at Robinsons RiverVANCOUVER, British Columbia, Sept. 14, 2026 (GLOBE NE…
Cotización
US$ 5,22
vs teórico
+2,24%
Cotización MEP implícita
$ 1.552,68
Cotización
—
vs teórico
—
Cotización Cable implícita
—
El precio teórico del CEDEAR VRTX se calcula dividiendo el precio de VRTX por el ratio (101). Hoy resulta en US$ 5,11.
En BYMA podés operar VRTX en pesos, VRTXD en dólar MEP y VRTXC en dólar cable. Cada modalidad refleja un tipo de cambio distinto.
En esta página encontrás un gráfico con el precio histórico del CEDEAR VRTX en pesos argentinos, con datos de data912.

Yahoo · 14 de sept de 2026
Amgen trades at a cheaper valuation but carries higher leverage, while Vertex boasts pristine finances and 32% net margins, a classic trade-off between value an…
SeekingAlpha · 14 de sept de 2026

Yahoo · 12 de sept de 2026
Vertex Pharmaceuticals (NASDAQ:VRTX) highlighted a series of upcoming clinical, regulatory and commercial catalysts across renal disease, pain management, cysti…

Yahoo · 12 de sept de 2026
Vertex Pharmaceuticals (NASDAQ:VRTX) outlined a broadening commercial and clinical strategy at the Cantor Global Healthcare Conference, highlighting its recent…

Yahoo · 11 de sept de 2026
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) could be positioning itself for its next major phase of growth following its roughly $10 billion acquisition o…
Noticias vía Finnhub